Latest Breaking News On - Prnewswire intensity therapeutics inc - Page 1 : comparemela.com

Intensity Therapeutics, Inc and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity s Lead Drug Candidate

Intensity Therapeutics, Inc and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity s Lead Drug Candidate
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesLewish benderJustin kulikJules abrahamIntensity therapeutics incCompany nasdaqEuropean unionSwiss cancer leagueSwiss group for clinical cancer researchPrnewswire intensity therapeutics incNational cancer instituteSwiss cancer research foundationCompetence centerSwiss groupClinical cancer researchCommon terminology criteria

Intensity Therapeutics, Inc And The Swiss Group For Clinical Cancer Research SAKK Sign A Collaboration

Intensity Therapeutics, Inc And The Swiss Group For Clinical Cancer Research SAKK Sign A Collaboration
wn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wn.com Daily Mail and Mail on Sunday newspapers.

Company nasdaqPrnewswire intensity therapeutics inc

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesLewish benderJules abrahamJustin kulikCompany nasdaqIntensity therapeutics incPrnewswire intensity therapeutics incIntensity therapeuticsRelations contactMonths ended march

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

FDA provides Study May Proceed letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024 SHELTON, Conn., Jan. 3, 2024.

United statesMerck sharpe dohmeJonathan nugentDavid rosenLewish benderBristol myers squibbChristian frederick meyerCompany nasdaqOttawa hospital research instituteOffice of orphan products developmentDrug administrationPrnewswire intensity therapeutics incOntario institute of cancer researchCompanya study mayIntensity therapeutics incInvestigational new drug

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesHofstra universityDavid rosenJoseph talamoJohn wesolowskiMerck sharpe dohmeCaladrius biosciencesJonathan nugentLewish benderBristol myers squibbCompany principal accountingIntensity therapeutics incOntario institute of cancer researchOttawa hospital research institutePrnewswire intensity therapeutics inc